The clinical recognition of pheochromocytoma as a cause of hypertension is still a difficult problem for which the many tests that have been devised are at times inadequate. In this article an antidiuretic response to piperoxan in patients with pheochromocytoma is described. In view of the diuretic response of patients without pheochromocytoma, measurement of urinary flow after injection of piperoxan is suggested as a possible simple, confirmatory guide in diagnosis.
IN NORMAL man infusions of epinephrine or norepinephrine tend to promote excretion of dilute urine at normal or increased rates of flow; the urine flow decreases sharply when the infusions are withdrawn.' The present report describes an analogous antidiuresis observed in patients with functioning pheochromocytoma in whom sudden partial withdrawal of adrenal medullary hormone was simulated by giving piperoxan (benzodioxane, 933 F) . Concurrent changes in other renal functions are also described. The responses to the drug are compared with those found in patients without functioning pheochromocytoma, from 2 of whom such tumors had been removed, and 6 of whom showed arterial hypertension at the time of the study.
In comparison with the many careful observations of the effect of this drug on arterial pressure2'3its effects on renal function have received scant attention. Further, the observations indicate that the response of urine flow to administration of piperoxan may be a useful confirmatory observation in the diagnosis of pheochromocytoma.
METHODS
The study is based on measurements of plasma clearances of para-aminohippurate at low plasma concentrations (CPAH) and mannitol (CM), urine flow (V), and arterial pressure by brachial auscultation (B.P.). The patients were not especially preFrom the Research Division of The Cleveland Clinic Foundation and the Frank E. Bunts Educational Institute, Cleveland, Ohio. Presented at the 28th Annual Scientific Session of the American Heart Association, New Orleans, La., October 23, 1955 . Abstracted, Circulation 12: 689, 1955 pared except that both tests in patient no. 7 were made after hydration by infusion of 1.5 L of 1 per cent NaCl over the 2 hours prior to the tests. Mannitol and PAH were given intravenously by infusion,4 after administration of priming doses. Urine was collected by catheterization and bladder washing at intervals of about 10 min. The rate of urine flow (V) was taken as the difference between measured volume of urine plus wash and volume of bladder wash, divided by the duration of the period in minutes. The observation in patient no. 9 differs in that PAH was given subcutaneously and mannitol was not given; changes of glomerular filtration rate in this patient were estimated from measurements of endogenous creatinine clearance (Ccr),* and periods of urine collection were extended over 30 min. Creatinine was measured by the method of Miller and Miller.5 The 4 patients with uncomplicated essential hypertension, 1 with hypertension due to acute glomerulonephritis, and patient no. 10 with functioning pheochromocytoma were each given 20 mg, of piperoxan intravenously over 1 to 3 min. at the end of the third urine collection; urine collections were then carried on for another 2 periods. Blood pressure was measured repeatedly prior to and following the injection; the values listed (table 1) are averages of 3 to 5 measurements made during each interval of urine collection. The patient with persistent hypertension after removal of a functioning pheochromocytoma (no. 6), the patient who attained normotension after removal of a pheochromocytoma (no. 7), and patient no. 8 with functioning pheochromocytoma were each observed during 3 control periods and 3 test periods and piperoxan was given during the test periods in repeated doses; in patient no. 9 the drug was infused intravenously at a steady rate of 2 mg./min.
Thus, the group studied consists of 7 "controls," including the postoperative observation of pheochromocytoma in patients no. 7 and 4. Clinical ANTII)IURESIS AND OTHER RENAL RESPONSES Corcoran) show that in the rat small doses of these agents elicit osmotic diuresis, apparently by inhibition of proximal tubular electrolyte reabsorption, while larger doses, which cause severe renal vasoconstriction, depress urine flow by decreasing filtration rate. The third antidiuretic mechanism may be increased liberation of posthypophyseal antidiuretic hormone; this mechanism is believed to account, in part, for the antidiuretic effect of withdrawal of infusions of norepinephrine and epinephrine in patients.'
The pressor, renal vasoconstrictor, and, commonly, diuretic responses to injected piperoxan observed in the "control" patients are unexplained except as they may depend on known vasomotor properties of piperoxan and, since it is known to act on the brain stem and central nuclei,8 possibly posthypophyseal inhibition.
While these mechanisms are speculative, the significant fact derived from these observations is that in patients with functioning pheochromocytoma, piperoxan has a strong antidiuretic activity, in contrast to its diuretic action in patients with hypertension due to causes other than pheochromocytoma.. The antidiuretic effect of piperoxan is proportionately greater than its effect on blood pressure and on the other renal functions tested. It is clear that, under standardized conditions of hydration and diuresis, measurement of changes in urine flow may provide a simple confirmatory observation in the clinical diagnosis of functioning pheochromocytoma and may be a guard against "false positive" piperoxan tests based only on observations of arterial pressure. SUMMARY Piperoxan was found to have a moderate renal vasodilatory effect and to decrease urine flow to about one third of the pretreatment rate when intravenously injected in patients with functioning pheochromocytoma. In contrast, it elicited slight renal vasoconstriction and usually increased urine flow when given to 6 patients with hypertension due to other causes and to 1 patient who had become normotensive after removal of a pheochromocytoma.
The antidiuretic effect of piperoxan in the presence of functioning pheochromocytoma probably reflects inhibition of the renal vascular and tubular actions of norepinephrine and epinephrine and, insofar as it may correspond to the antidiuresis elicited by withdrawal of infusions of epinephrine or norepinephrine, may also involve posthypophyseal antidiuretic action. The diuretic effect of piperoxan in subjects without pheochromocytoma is probably due to a similar complex response.
The antidiuretic effect of piperoxan in patients with pheochromocytoma is larger proportionately than its effect on blood pressure, so that measurement of urine flow under standardized conditions should be a simple, confirmatory sign in the diagnosis of this condition.
SUMMARIO IN INTERLINGUA Esseva constatate que piperoxano ha un moderate effecto vasodilatatori renal e reduce le fluxo urinari a circa un tertio del nivello pre-tractamental quando illo es injicite intravenosemente in patientes con pheochromocytoma functionante. Del altere latere, le droga causava leve grados de vasoconstriction renal e usualmente un augmentate fluxo urinari quando illo esseva administrate a 6 patientes con hypertension debite a altere causas e a 1 patiente qui habeva redevenite normotensive post le ablation de un pheochromocytoma.
Le effecto antidiuretic de piperoxano in le presentia de pheochromocytoma functionante reflecte probabilemente un inhibition del effecto de norepinephrina e epinephrina super le activitate reno-vascular e reno-tubular. In tanto que illo corresponde al antidiurese evocate per le suppression de infusiones de epinephrina o norepinephrina, illo pote etiam involver un action antidiuretic posthypophyseal. Le effecto diuretic de piperoxano in subjectos sin pheochromocytoma es probabilemente le resultato de un responsa similemente complexe.
Le effecto antidiuretic de piperoxano in patientes con pheochromocytoma es proportionalmente plus grande que su effecto super le pression sanguinee, de maniera que le mesuration del fluxo urinari sub conditiones standardisate deberea esser un simple signo confirmatori in le diagnose de iste condition. . This 61-year-old woman (patient of Dr. Robert Schneider) complained of "spells" and diabetes. Piperoxan was deeply depressor on 2 occasions, as was also phentolamine (Regitine), while histamine and dimethyl-fluorophosphate were pressor. A pheochromocytoma weighing 35 Gm. was removed from the region of the right adrenal gland and yielded 0.29 mg./Gm. of epinephrine and 0.34 mg./Gm. of norepinephrine (colorimetric assay with iodine). The arterial pressure remained elevated postoperatively, although specific tests were negative for pheochromocytoma. She was readmitted for re-exploration on the assumption that there might be a contralateral pheochromocytoma, at which time the test of renal function was done. A 5-Gm. tumor was removed from the left adrenal gland; this contained by pressor assay in the dog the equivalent of 0.1 mg./Gm. pressor urine as compared with norepinephrine and was histologically a coitical adenoma. The urine was examined by Dr. M. Goldenberg, who failed to find increased amounts of catecholamine; postoperatively, as preoperatively, piperoxan was pressor in test doses and Regitine depressor.
Patient no. 7 (673-532). This woman of 47 years was seen in August 1952 because of nervousness, sweating, palpitation, and weight loss with lower abdominal pain. The process seems to have started in 1950; in June 1951 she had been hospitalized because of "nervous collapse," consulted a psychiatrist in September of that year and, following discovery of elevated basal metabolic rate (+22), in November was treated ineffectually with propylthiouracil. Histamine was pressor and the effect was reversed with piperoxan. Dimethyl-fluorophosphate (DMPP) was pressor and Regitine depressor.
Basal metabolism was measured as +50 per cent. The urine contained increased amounts of catecholamine (bioassay and iodine colorimetry) of 225)
